Increased – Talk Bio

J&J brushes off tariff headwinds with raised forecast, oncology surge

1 week ago talkbio0Tagged Caplyta, Growth, Increased, Intra-Cellular Therapies, J&J, Johnson and Johnson, Neoplasms, Projections and Predictions, Raised, Sales - occupational activity, United States

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation

1 month ago talkbio0Tagged aligns, announcement, Benefit, capabilities, commitment, Corporation, domestic pharmaceutical industry, Increased, innovation, Investments, J&J 's, Manufacturing, Surgical construction, trends qualifier, United States

This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.

Pharmaceutical Industry Warns of Drug Shortages and Price Hikes Due to Trump’s New Tariffs

3 months ago talkbio0Tagged Active, APIs, chain disruption, Drug Industry, Drug shortages, Groups, Increased, Prices, TNFRSF19 gene, Trump tariffs

Trump tariffs, drug shortages, price increases, pharmaceutical industry, trade groups, supply chain disruption, generic drugs, active pharmaceutical ingredients (APIs)

ICER Report Highlights Unjustified Price Hikes on Five Brand-Name Drugs, Costing U.S. $815 Million in 2023

4 months ago talkbio0Tagged Biktarvy, Cabometyx, CREM gene, Darzalex, drug price, Entresto, Increased, Johnson & Johnson, Novartis, pharmaceutical companies, Prices

ICER, unsupported price increases, drug price hikes, pharmaceutical companies, Gilead Sciences, Johnson & Johnson, Novartis, Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz.

GSK Shifts Focus from Acquired Vaccine to Preclinical Successor Due to Increased Competition

6 months ago talkbio0Tagged Affinivax, competition, Increased, MAPS technology, Pneumococcal vaccine, Preclinical Successor, SmithKline Beecham, Vaccines

GSK, vaccine, preclinical successor, increased competition, pneumococcal vaccine, Affinivax, MAPS technology

Gilead’s Magrolimab Linked to Increased Risk of Death in Blood Cancer Patients

10 months ago talkbio0Tagged Clinical Research, Enhance (action), Gilead, Hematologic Neoplasms, Increased, magrolimab, Risk of Death

Gilead, Magrolimab, Blood Cancer, Increased Risk of Death, ENHANCE Study

GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59

11 months ago talkbio0Tagged Adult, Age, Approved, Arexvy, Asthma, Chronic Obstructive Airway Disease, Diabetes, Heart failure, Increased, medical conditions, Respiratory syncytial virus, Respiratory Tract Diseases, Risk, SmithKline Beecham, United States Food and Drug Administration, Vaccines

GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.

CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements

1 year ago talkbio0Tagged Administrative action, Burden, Casgevy, Cells, Centers for Medicaid and Medicare (CMS) Pnl, Central, CGT, Equitable Access, Fertility, Grail, Increased, Lyfgenia, Medicaid Access, Medicare & Medicaid Services, OBAs, Outcomes-Based Agreements, Reimbursement, sickle cell gene therapies

CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction